Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0091 | 0.4091 | 0.5 | |
Brugia malayi | RNA binding protein | 0.0141 | 0.7242 | 1 |
Giardia lamblia | Kinase, CMGC MAPK | 0.0058 | 0.2024 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.0058 | 0.2024 | 0.5 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.0058 | 0.2024 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0185 | 1 | 1 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.0058 | 0.2024 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0141 | 0.7242 | 0.6542 |
Entamoeba histolytica | hypothetical protein | 0.0025 | 0 | 0.5 |
Echinococcus multilocularis | L aminoadipate semialdehyde | 0.0091 | 0.4091 | 0.2592 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.0058 | 0.2024 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0058 | 0.2024 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0141 | 0.7242 | 1 |
Plasmodium falciparum | holo-[acyl-carrier-protein] synthase, putative | 0.0025 | 0 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0141 | 0.7242 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0058 | 0.2024 | 0.5 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.0058 | 0.2024 | 1 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0058 | 0.2024 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0141 | 0.7242 | 0.6542 |
Mycobacterium tuberculosis | holo-[acyl-carrier protein] synthase AcpS (holo-ACP synthase) (CoA:APO-[ACP]pantetheinephosphotransferase) (CoA:APO-[acyl-carrie | 0.0025 | 0 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0141 | 0.7242 | 1 |
Treponema pallidum | 4'-phosphopantetheinyl transferase | 0.0025 | 0 | 0.5 |
Schistosoma mansoni | aminoadipate-semialdehyde dehydrogenase | 0.0091 | 0.4091 | 0.2592 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0058 | 0.2024 | 0.5 |
Mycobacterium leprae | conserved hypothetical protein | 0.0025 | 0 | 0.5 |
Mycobacterium ulcerans | phosphopantetheinyl transferase, PptII | 0.0025 | 0 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0141 | 0.7242 | 0.6542 |
Brugia malayi | aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase | 0.0091 | 0.4091 | 0.3962 |
Wolbachia endosymbiont of Brugia malayi | 4'-phosphopantetheinyl transferase | 0.0025 | 0 | 0.5 |
Echinococcus granulosus | L aminoadipate semialdehyde | 0.0091 | 0.4091 | 0.2592 |
Plasmodium vivax | holo-[acyl-carrier-protein] synthase, putative | 0.0025 | 0 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0141 | 0.7242 | 1 |
Trypanosoma brucei | protein kinase, putative | 0.0058 | 0.2024 | 1 |
Chlamydia trachomatis | holo [acyl-carrier protein] synthase | 0.0025 | 0 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0141 | 0.7242 | 0.6542 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.0058 | 0.2024 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0141 | 0.7242 | 0.6542 |
Mycobacterium ulcerans | 4'-phosphopantetheinyl transferase | 0.0025 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0185 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0058 | 0.2024 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0058 | 0.2024 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0141 | 0.7242 | 0.6542 |
Loa Loa (eye worm) | hypothetical protein | 0.0091 | 0.4091 | 0.3962 |
Loa Loa (eye worm) | RNA binding protein | 0.0141 | 0.7242 | 1 |
Echinococcus multilocularis | geminin | 0.0185 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0141 | 0.7242 | 0.6542 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.